Eisai Europe Ltd.
HATFIELD, England, June 1, 2011 -
Preliminary results of a Phase II study to be presented at the
American Society of Clinical Oncology (ASCO) Annual Meeting showed that
Eisai's E7080 (lenvatinib [USAN]) demonstrated an Objective Response Rate
(ORR) of 59% (34/58, 95% CI:45 - 71),[2] based on an updated investigator
assessment, in patients with advanced radioiodine (RAI)-refractory
differentiated thyroid cancer (DTC).[1] These results will be presented
during an ASCO oral session on June 6, 2011.
HATFIELD, England, January 21, 2011 - The Committee for Medicinal Products for Human Use (CHMP), the scientific
committee of the European Medicines Agency (EMA), today gave a positive
opinion for the use of Eisai Europe, Ltd.'s Halaven as a monotherapy
indicated in the treatment of patients with locally advanced (LA) or
metastatic breast cancer (MBC) who have progressed after at least two
chemotherapeutic regimens for advanced disease.
MILAN, October 10, 2010 - Further results from the Phase III EMBRACE study presented today at the
European Society of Medical Oncology (ESMO) congress showed that Eisai's
eribulin mesylate maintained an overall survival (OS) benefit compared with
Treatment of Physician's Choice (TPC) in metastatic breast cancer (MBC)
patients, irrespective of their tumour hormone receptor status, extent of
disease or prior therapy.[1]
Additional analyses of the EMBRACE study (Eisai Metastatic Breast Cancer
Study Assessing Physician's Choice Versus Eribulin E7389) investigated the
primary endpoint of OS benefit of eribulin versus TPC within several
pre-specified sub-groups, including: hormone receptor expression status,
number of organs involved, sites of disease and prior treatment with
capecitabine.
HATFIELD, England, August 24, 2010 - Eisai today announced the results of a Phase III study for the
investigational compound perampanel (E2007), a first-in-class, highly
selective non-competitive AMPA-type glutamate receptor antagonist, discovered
by Eisai and under development for adjunctive treatment of partial seizures
in patients with epilepsy.
